Member Info for HarChris

Money really isn't all that tight, they have runway into Q1 2027 which takes them through all the p1b readouts and nine months of 6103 data.. BBN made the important point this morning that actual cash required to fund Avacta right now is relatively low, requiring 7% dilution per year to finance its programmes. Land any sort of deal for SGC with some upfront cash and that likely raises share price, relieves future cash requirements and means any further funding needed would be but the weeniest of dilution to take 6103 right through 2027.

One is clearly in just 10 days time, ASCO. The other later in H1. It's close.

Let's assume for example that just 10 TNBC patients have been dosed... there were none in p1a so how do they take that forward however positive the results are from those patients? Focusing on one indication is pragmatism rather than a sign of ava6000 failure.

This is a small cap biotech with extremely limited resources, the likelihood is that those limited resources have had to be directed at SGC and therefore there are multiple more SGC patients dosed than TNBC or STS and so simply too small a sample at this stage to progress further by themselves.

There was but indirectly: 'We expect multiple data updates in the AVA6000 program in all groups from the Phase 1b expansion cohorts, in H1 2026.''

STS only mention once directly.

Probably more like £700k in the bank at this stage. We need Raglan to start meaningfully contributing to avoid a H2 placing, still every chance of that happening.

I know that's to Pedro but my answer is 'yeah, why not?'. There's no expectation of a deal landing tomorrow, there's no run up in share price since preliminary results announcement, it's just last year's financials. The hope is for a deal around ASCO.

Go on then tell me how much it says it costs per RNS? I saw this on a discussion board recently around per cost release:

''We were paying per announcement, but we’ve taken out a subscription this year which is saving us money as we have a share buy back scheme in progress and are making daily announcements. It’s user friendly – you can import Word documents, cut and paste, etc.

Typical per use costs were £31 per disclose announcement.''

It wouldn't be the end of the world if SQM walked away from the JV because the scale just isn't great enough for them as a $25B dollar mining giant. That would mean considerable funds invested into the project before handing back 100% ownership to Andrada.

Either way it does seem likely this will be a meaning project to Andrada worth more than their current $115m mcap.

Yeah but that's all known beforehand, the cash they have is at best taking them through to January meaning a placing needed in Q4 unless there's a licencing/partnership deal. Even then only pushes runway out a bit further unless the upfront cash is sizeable.

If it was considerably more than £100 you would find it's prohibitive for nano stocks with barely any cash to their name yet they often still churn out RNS'. I think more substantial news releases might cost a bit more but I remember being told it generally cost around that.

I think it's counter productive to hype up tomorrow, it's just the yearly results update, it'll likely be a non event with the best case being no surprises... the ASCO publications on Thursday evening followed by an (hopefully) RNS Friday is the one more likely to have an impact/ be of significant importance.

Completely agree with your analysis triplestar. This has now gone from relatively low risk/medium reward to higher risk/higher reward.

Went from having bags of time to get Raglan performing in order to fund Blue Mountain and be a debt free producer to requiring delivery in the short term now. Half of the £1.5m will have been spoken for now so Raglan needs to contribute to keep that balance healthy and through to Maddens adding rather than consuming. And ideally enough to cover the AUD$2m due in November.

If successful this won't be anywhere near today's £8.5m but plenty of uncertainty in the meantime.

What’s more important than actual sales growth is margin improvement and actually turning a profit, something that should be hugely helped by the integration of the three brands into one.

Let’s see signs of that in the next update and a near term target for group profitability.

Avacta are a £400m company where the difference of being well funded or not is £20m or so - there is no discussion going on behind the scenes about rationing RNS’ to save £100 a pop.

One of your funniest takes.

They always release them well before due date of 30th June, in some years it was in April. Nothing to read in to this good or bad.

You can keep repeating this all you like but it's incorrect.

The CLN is for £2m (AUD3.86) and is to be converted at 0.26p in eighteen months time. The interest looks to be about 8% over the lifetime of the loan so very reasonable in this climate. ECR also has the right to redeem at any time so if they do achieve their aim of producing from 3 sites by the end of the year then ECR will have plenty of options - for example if the share price rallies then raise at that price and then pay off the CLN in cash, with the money raised/accumulated profit.

Essentially what this debt has done is force ECR to deliver within the next eighteen months and if they don't they will run into major trouble at the end of 2027... but let's be honest, if that is the case we're losing our money here anyway.

I fully back them to be meaningfully producing gold within that timeframe.

for me the trustpilot reviews are extremely reassuring. i would imagine about 10% of deliveries end up with a review and so maybe around the 1500 order level per week at the mo? more importantly people are far more likely to review if they've had a bad experience that good so if we're talking just a few handfuls of bad reviews out of around 1500 orders that's very good going. plus discount shoppers are discerning so are likely to be even more ****ed off with bad service / probably include some that are constantly complaining and looking for returns / freebies.

just hoping the next update, which must be soon, shows enough clear signs of positive progress being made from all the recent operational moves. then the rerate begins from the heavily depressed level.

Come on Thorn go back to troll school and make a new account and do a better job of pretending your some random curious avacta sceptic. It's almost sad how bad you are at this.

That almost sounded sexual.

Much more likely that they sell the company once they’ve built it to stable profitability. And that price will at least be a few multiples from where we are today.